CA2316994A1 - Composition et procede pour la prevention et le traitement de l'insuffisance cardio-pulmonaire et renale, ou des lesions consecutives a l'ischemie, la liberation d'endotoxines, l'emphyseme pulmonaire ou a l'administration de certains medicaments - Google Patents

Composition et procede pour la prevention et le traitement de l'insuffisance cardio-pulmonaire et renale, ou des lesions consecutives a l'ischemie, la liberation d'endotoxines, l'emphyseme pulmonaire ou a l'administration de certains medicaments Download PDF

Info

Publication number
CA2316994A1
CA2316994A1 CA002316994A CA2316994A CA2316994A1 CA 2316994 A1 CA2316994 A1 CA 2316994A1 CA 002316994 A CA002316994 A CA 002316994A CA 2316994 A CA2316994 A CA 2316994A CA 2316994 A1 CA2316994 A1 CA 2316994A1
Authority
CA
Canada
Prior art keywords
seq
fragment
adenosine
agents
gat gga
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002316994A
Other languages
English (en)
Inventor
Jonathan W. Nyce
Jeffrey L. Hill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epigenesis Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/093,972 external-priority patent/US6825174B2/en
Application filed by Individual filed Critical Individual
Publication of CA2316994A1 publication Critical patent/CA2316994A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant un agent tel qu'un agoniste de l'adénosine A2a et/ou un acide nucléique comprenant un olugonucléotide(oligo) antisense d'un gène récepteur de l'adénosine A1, A2a, A2b ou A3, de l'ARN médiateur, des régions bordures ou des régions passerelles entre les bordures intro/exon. Ces oligo sont capables de prévenir, de soulager ou d'inhiber des troubles fonctionnels, des lésions ou des insuffisances d'ordre cardiaque, pulmonaire et/ou rénal à médiation de l'adénosine, tels que ceux rencontrés dans le cas de pathologies telles que l'emphysème pulmonaire et l'hypoxie ou consécutives à l'administration de certains agents thérapeutiques ou de diagnostic tels que la cysplatine d'adénosine, des agents contenant des ions métalliques, ou certains de leurs mélanges, et éventuellement un tensioactif, un vecteur et d'autres agents thérapeutiques et de diagnostic ainsi que d'autres composants de formulations. La composition proposée se présente sous diverses formulations qui conviennent notamment au traitement ou au soulagement de la bronchoconstriction, des allergies et/ou des inflammations associées à l'emphysème pulmonaire chronique ou aigü, aux effets secondaires observés à la suite du traitement de la tachycardie supraventriculaire, à la suite de l'administration de tests du stress cardiaque ou de tests d'imagerie.
CA002316994A 1998-06-08 1999-06-08 Composition et procede pour la prevention et le traitement de l'insuffisance cardio-pulmonaire et renale, ou des lesions consecutives a l'ischemie, la liberation d'endotoxines, l'emphyseme pulmonaire ou a l'administration de certains medicaments Abandoned CA2316994A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8850198P 1998-06-08 1998-06-08
US60/088,501 1998-06-08
US8865798P 1998-06-09 1998-06-09
US09/093,972 US6825174B2 (en) 1995-06-07 1998-06-09 Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
US60/088,657 1998-06-09
US09/093,972 1998-06-09
PCT/US1999/012775 WO1999063938A2 (fr) 1998-06-08 1999-06-08 Composition et procede pour la prevention et le traitement de l'insuffisance cardio-pulmonaire et renale, ou des lesions consecutives a l'ischemie, la liberation d'endotoxines, l'emphyseme pulmonaire ou a l'administration de certains medicaments

Publications (1)

Publication Number Publication Date
CA2316994A1 true CA2316994A1 (fr) 1999-12-16

Family

ID=27375993

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002316994A Abandoned CA2316994A1 (fr) 1998-06-08 1999-06-08 Composition et procede pour la prevention et le traitement de l'insuffisance cardio-pulmonaire et renale, ou des lesions consecutives a l'ischemie, la liberation d'endotoxines, l'emphyseme pulmonaire ou a l'administration de certains medicaments

Country Status (4)

Country Link
EP (1) EP1011608A4 (fr)
AU (1) AU4675699A (fr)
CA (1) CA2316994A1 (fr)
WO (1) WO1999063938A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
JP2003535818A (ja) * 2000-02-17 2003-12-02 スィーヴィー セラピューティクス インコーポレイテッド 哺乳動物細胞増殖を媒介するａ２ｂアデノシンリセプタ拮抗剤の同定および使用方法
CA2439222C (fr) 2000-02-23 2009-07-14 Cv Therapeutics, Inc. Procede permettant d'identifier des agonistes partiels du recepteur a2a
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
AU2002362443B2 (en) 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
NZ537975A (en) 2002-07-29 2007-08-31 Cv Therapeutics Inc Method of producing coronary vasodilation without peripheral vasodilation comprising administering at least 10 mcg of at least one A2A receptor agonist
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
WO2006028618A1 (fr) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation Analogues d'adenosine de propynyle 2-polycyclique presentant des groupes 5'-ribose modifies presentant une activite agoniste de a2a
EP2266994B1 (fr) 2004-08-02 2013-04-03 University Of Virginia Patent Foundation Analogues de 2-propynyle adenosine comprenant des groupes 5'-ribose modifies presentant une activite agoniste A2A
JP2008517063A (ja) 2004-10-20 2008-05-22 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ａアデノシンレセプターアゴニストの使用
CA2640089C (fr) 2006-02-03 2013-07-23 Cv Therapeutics, Inc. Procede de preparation d'un agoniste de recepteur a2a-adenosine et ses polymorphes
CA2655310A1 (fr) * 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Utilisation d'agonistes de recepteur d'adenosine a<sb>2a</sb> dans le traitement d'une ischemie
CN102036689B (zh) 2008-03-17 2014-08-06 得克萨斯系统大学董事会 神经肌肉突触维持和再生中涉及的微小rna的鉴定

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994315A (en) * 1995-06-07 1999-11-30 East Carolina University Low adenosine agent, composition, kit and method for treatment of airway disease
US6040296A (en) * 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
US6025339A (en) * 1995-06-07 2000-02-15 East Carolina University Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation

Also Published As

Publication number Publication date
EP1011608A2 (fr) 2000-06-28
WO1999063938A2 (fr) 1999-12-16
WO1999063938A3 (fr) 2000-01-27
WO1999063938A9 (fr) 2000-03-02
AU4675699A (en) 1999-12-30
EP1011608A4 (fr) 2002-05-15

Similar Documents

Publication Publication Date Title
CA2316994A1 (fr) Composition et procede pour la prevention et le traitement de l&#39;insuffisance cardio-pulmonaire et renale, ou des lesions consecutives a l&#39;ischemie, la liberation d&#39;endotoxines, l&#39;emphyseme pulmonaire ou a l&#39;administration de certains medicaments
US6040296A (en) Specific antisense oligonucleotide composition &amp; method for treatment of disorders associated with bronchoconstriction and lung inflammation
US6025339A (en) Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
US5994315A (en) Low adenosine agent, composition, kit and method for treatment of airway disease
AU752531B2 (en) Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications
WO1998023294A9 (fr) Agent et methode de traitement de maladies et d&#39;etats pathologiques associes a des malaises respiratoires et a une inflammation pulmonaire
US9006203B2 (en) Method of reducing inflammatory infiltration in subjects with inflammatory lung disease
US6825174B2 (en) Composition, formulations &amp; method for prevention &amp; treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) &amp; inflammation
WO2000051621A1 (fr) Procede de validation/d&#39;invalidation de cibles et des voies
RU2416412C2 (ru) Антисмысловые олигонуклеотиды для лечения аллергии и пролиферации неопластических клеток
US20050014711A1 (en) Composition, formulations &amp; methods for prevention and treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) and inflammation
MXPA00004001A (es) Composicion y metodo para la prevencion y tratamiento de insuficiencia o dano cardiopulmonar y renal asociado con isquemia, liberacion de endotoxinas, sindrome de esfuerzo respiratorio agudo o provocado por la administracion de ciertos farmacos.
AU699330C (en) Method of treatment for asthma
AU724817B2 (en) Method of treatment for asthma
AU753972B2 (en) Low adenosine oligonucleotide, composition, kit and methods for obtaining oligonucleotide and for treatment of airway disease(s)
MXPA00002640A (en) Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications
MXPA97009866A (en) Method for the treatment of pulmon diseases using oligonucleotides antisent
KR20020095600A (ko) 아데노신 함량이 낮은 안티센스 올리고뉴클레오타이드,조성물, 키트 및 기관지수축, 폐염증, 알레르기(들) 및계면활성제 결핍와 관련된 기도 장애들의 치료 방법

Legal Events

Date Code Title Description
FZDE Discontinued